MedTech News

New gene switch activates with simple skin patch and could help treat diabetes
ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin. One day, researchers want to use switches of this kind to trigger cell therapies for various metabolic diseases.

CereVasc Receives Approval for STRIDE Clinical Trial of the eShunt® System for the Treatment of Elderly Patients with Normal Pressure Hydrocephalus in Argentina
BOSTON, Feb. 13, 2025 /PRNewswire/ — CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, announced today that it has received approval from Argentina’s National Administration of Drugs, Food and Medical Devices (ANMAT) to initiate the STRIDE trial, a clinical study evaluating CereVasc’s eShunt System as a treatment for normal pressure hydrocephalus (NPH).

RFK Jr. wins Senate confirmation as HHS secretary
The U.S. Senate voted 52–48 today to confirm Robert F. Kennedy Jr. as the new secretary of the U.S. Department of Health and Human Services.

Allurion relaunches weight loss balloon in France
Allurion Technologies (NYSE:ALUR) today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume sales.

Subtle Medical’s SubtleHD™ Awarded FDA Clearance, Setting a New Benchmark for MRI Image Quality and Speed
With FDA clearance of SubtleHD™, Subtle Medical launches Subtle-ELITE™, an industry-first AI package designed to achieve superior image quality, unprecedented speed, and workflow automation

Wearable carbon dioxide sensor can enable real-time apnea diagnosis
Professor Seunghyup Yoo’s research team in the Department of Electrical and Electronic Engineering developed the low-power, high-speed wearable CO2 sensor capable of stable breathing monitoring in real time.

Gene ‘silencer’ in junk DNA prevents fatal neurological disease
A team led by University of Pittsburgh School of Public Health geneticists has shown, for the first time, that a gene “silencer” that resides in junk DNA is directly sparing people from a devastating and fatal progressive neurological disease.

Implantica announces Module 1 is accepted and closed by FDA in the PMA application for RefluxStop™
VADUZ, Liechtenstein, Feb. 12, 2025 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, is pleased to announce that the FDA has accepted Module 1 of the company’s premarket approval (PMA) application, and that this module is now considered closed.